Alvotech (ALVO)
| Market Cap | 1.03B -58.6% |
| Revenue (ttm) | 562.04M -4.4% |
| Net Income | -80.73M |
| EPS | -0.26 |
| Shares Out | 313.02M |
| PE Ratio | n/a |
| Forward PE | 22.71 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 277,555 |
| Open | 3.240 |
| Previous Close | 3.250 |
| Day's Range | 3.200 - 3.315 |
| 52-Week Range | 3.030 - 11.850 |
| Beta | 0.21 |
| Analysts | Buy |
| Price Target | 15.80 (+381.71%) |
| Earnings Date | May 6, 2026 |
About ALVO
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat variou... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ALVO stock is "Buy." The 12-month stock price target is $15.8, which is an increase of 381.71% from the latest price.
News
Alvotech Transcript: Bank of America Global Healthcare Conference 2026
Recent launches and a robust pipeline position the company for limited-competition biosimilar entries, with regulatory remediation on track for key approvals by year-end. Expanded manufacturing and strategic partnerships support growth, while industry consolidation and regulatory changes enhance competitive positioning.
Alvotech announces cGMP surveillance inspection of Reykjavik facility
Alvotech (ALVO) announces that the FDA has completed a routine cGMP surveillance inspection of the company’s manufacturing facility in Reykjavik, Iceland. At the conclusion of the inspection on May 8,...
Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility
- Company remains on track for BLA resubmissions in the second quarter REYKJAVIK, Iceland, May 11, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializi...
Alvotech Earnings Call Transcript: Q1 2026
Q1 2026 saw revenues decline 20% year-over-year to $106 million due to facility improvements, but gross margin improved and EBITDA margin rose to 23%. Regulatory progress, new launches, and a strategic FUJIFILM partnership position the company for strong growth in 2027.
Alvotech Earnings release: Q1 2026
Alvotech released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Alvotech Slides: Q1 2026
Alvotech has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Alvotech Q1 2026 Financial Results
Alvotech (NASDAQ US: ALVO, ICELAND: ALVO, STOCKHOLM: ALVO SDB) Financial Highlights A supplemental long ‑ form earnings release providing additional operational details and business update for Q1 202...
Alvotech Announces a Change in its Executive Team
REYKJAVIK, ICELAND (April 30, 2026) — Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, ...
Alvotech to Report Financial Results for the First Quarter of 2026
REYKJAVIK, Iceland, April 24, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar m...
Alvotech files Annual Report with the SEC
REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has filed its Annual Report 2025 on Form 20-F for the financial year 2025 with the U.S. Securities and Exchange Commissio...
Alvotech Publishes 2025 Annual Report
REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has published its Annual Report for 2025. The report is available in the investor relations section of Alvotech's website...
Alvotech price target lowered to $4 from $8 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Alvotech (ALVO) to $4 from $8 and keeps a Hold rating on the shares. The firm updated the company’s model post the…
Alvotech price target lowered to $4 from $5 at Barclays
Barclays lowered the firm’s price target on Alvotech (ALVO) to $4 from $5 and keeps an Underweight rating on the shares. The firm expects the shares to “remain in a…
Alvotech price target lowered to $6 from $10 at UBS
UBS lowered the firm’s price target on Alvotech (ALVO) to $6 from $10 and keeps a Buy rating on the shares. The firm is confident in the remediation plan outlined…
Alvotech price target lowered to $4 from $5 at Barclays
Barclays lowered the firm’s price target on Alvotech (ALVO) to $4 from $5 and keeps an Underweight rating on the shares. While the firm remains bullish on the long-term outlook…
Alvotech Earnings Call Transcript: Q4 2025
2025 saw 21% revenue growth to $593M and 27% higher adjusted EBITDA, driven by licensing and new launches. Guidance for 2026 is $650–$700M revenue, with U.S. launches providing upside. Regulatory remediation and expanded manufacturing underpin future growth.
Alvotech Annual report: Q4 2025
Alvotech has published its Q4 2025 annual report on March 19, 2026.
Alvotech Earnings release: Q4 2025
Alvotech released its Q4 2025 earnings on March 19, 2026, summarizing the period's financial results.
Alvotech Slides: Q4 2025
Alvotech has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 19, 2026.
Alvotech Q4 2025 and Full Year 2025 Financial Results
A supplemental long ‑ form earnings release providing additional operational details and business update for Q4 2025 and the full year is available at: https://investors.alvotech.com/earnings-calendar...
Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results
REYKJAVIK, ICELAND (March 4, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldw...
Alvotech Announces Increase in Number of Own Shares
REYKJAVIK, ICELAND (February 11, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwi...
Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
REYKJAVIK, ICELAND (February 5, 2026) – Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announce...
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
REYKJAVIK, ICELAND (February 2, 2026) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today an...
Alvotech Slides: SEB Nordic Seminar presentation
Alvotech has posted slides in relation to its latest quarterly earnings report, which was published on January 8, 2026.